logo

BALAXI vs FERMENTA: Stock Comparison

BALAXI PHARMA vs FERMENTA BIOTECHUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

FERMENTA BIOTECH is the larger company by market capitalisation. BALAXI PHARMA shows a lower P/E and lower leverage, while FERMENTA BIOTECH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BALAXI leads 3; FERMENTA leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BALAXIFERMENTA

Valuation lens

What price are you paying?

Market CapContext only
₹120 Cr
₹1,354 Cr
P/E RatioBALAXI has the lower reading
12.63x ✓
22.61x
P/B RatioBALAXI has the lower reading
0x ✓
3.33x
EPSFERMENTA has the higher reading
₹0.24
₹3.31 ✓
Book ValueContext only
₹45.12
₹136.1
Dividend YieldFERMENTA has the higher reading
0%
0.81% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
FERMENTA is the larger company
₹1,354 Cr vs ₹120 Cr
P/E Ratio
BALAXI has a lower P/E
12.63x vs 22.61x
P/B Ratio
BALAXI has a lower P/B
0x vs 3.33x
EPS
FERMENTA has higher earnings per share
₹3.31 vs ₹0.24
Dividend Yield
FERMENTA has a higher dividend yield
0.81% vs 0%
Revenue Growth (TTM YoY)
FERMENTA has faster revenue growth
0% vs -25.76%
EPS Growth (TTM YoY)
FERMENTA has faster EPS growth
0% vs -58.44%
ROE
FERMENTA has a higher ROE
15.2% vs 0.57%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBALAXIFERMENTA
SectorHealthcare—
IndustryPharmaceuticals—

Price

MetricBALAXIFERMENTA
Live Price₹21.76₹460.5
Day Change-1.49%-5.25%
Volume19,90084,469
52-Week High₹43.85₹582.65
52-Week Low₹15.2₹248.85
Distance from 52W High-50.38%-20.96%

Valuation

MetricBALAXIFERMENTA
Market Cap₹120 Cr₹1,354 Cr
P/E Ratio12.63x22.61x
P/B Ratio0x3.33x
EPS₹0.24₹3.31
Book Value₹45.12₹136.1
Dividend Yield0%0.81%

Growth

MetricBALAXIFERMENTA
Revenue Growth (TTM YoY)-25.76%0%
EPS Growth (TTM YoY)-58.44%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricBALAXIFERMENTA
ROE0.57%15.2%
ROCE0.85%13.88%
Net Margin0.52%13.37%
Operating Margin3.4%22.37%
Debt to Equity0.22x0.26x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricBALAXIFERMENTA
Promoter Holding65.99%56.47%
FII Holding0%0.13%▲ 0.11 pp
DII Holding2.56%0.04%▲ 0.04 pp
Public Holding31.45%33.2%▼ 0.1 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALAXI PHARMA and FERMENTA BIOTECH.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.